Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $6,749,952.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 10,880 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $620.40, for a total transaction of $6,749,952.00. Following the completion of the sale, the chief executive officer directly owned 504,273 shares of the company’s stock, valued at approximately $312,850,969.20. This represents a 2.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Medpace Price Performance

NASDAQ MEDP opened at $617.15 on Thursday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The firm has a market capitalization of $17.22 billion, a PE ratio of 36.18, a P/E/G ratio of 2.81 and a beta of 1.15. The company’s 50 day simple moving average is $591.38 and its 200 day simple moving average is $514.21.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 earnings per share. The company’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Royal Bank Of Canada increased their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. TD Cowen lifted their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $595.20.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently modified their holdings of MEDP. BlackRock Inc. purchased a new stake in shares of Medpace during the 2nd quarter worth about $1,323,047,000. State Street Corp increased its stake in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after purchasing an additional 28,666 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Wasatch Advisors LP lifted its stake in shares of Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after purchasing an additional 125,625 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after buying an additional 38,760 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.